Yes — in most studies a participant can travel during a clinical trial, provided the visit schedule is protected. The risk is not the holiday itself, it is the missed or out-of-window visit that follows. When a study is designed with home visits, a qualified study nurse can perform the scheduled assessment at the participant’s holiday address instead of at the investigator site. Deltaclinical facilitates these visits worldwide, including cross-border visits arranged while a participant is abroad, so the data point is collected on time and the participant stays in the study.
This article explains why holiday periods generate protocol deviations, which visit types can realistically be delivered at a holiday address, and how far in advance to plan.
Why holiday periods create protocol deviations
Clinical trial visit windows do not pause in July and August. A participant on a four-week holiday in another country may have two scheduled assessments fall inside that period. Traditionally, there are three outcomes, and none of them are good.
The participant cancels the holiday. This happens more often than sponsors realize, and it quietly damages the participant experience. Trial participation is already demanding, asking someone to give up family time on top of it increases the likelihood they will withdraw later.
The participant travels, and the visit is missed. A missed visit becomes a protocol deviation. Depending on the assessment, it can mean a gap in the efficacy dataset, an unmonitored safety window, or an interruption in investigational medicinal product (IMP) supply.
The participant withdraws. Dropout during holiday periods is a retention problem that rarely shows up as such in the data. The withdrawal is recorded weeks later, attributed to burden or logistics, and the underlying cause (an inflexible visit schedule) is never addressed.
Rare disease and CNS studies feel this most acutely. Recruitment is already difficult, participants are often geographically dispersed, and a single dropout can represent a meaningful percentage of the cohort.
What a home visit abroad actually looks like
A cross-border home visit is a scheduled study visit performed by a qualified nurse at the participant’s temporary address, following the same protocol, the same source documentation requirements, and the same quality standards as a visit performed at home or at the site.
In practice the sequence is straightforward:
- The participant informs the site of their travel dates and destination, ideally at the start of the study or as soon as the trip is booked.
- The site or sponsor notifies the home visit provider with the destination, dates, and the visits that fall inside the travel window.
- The provider identifies a qualified, protocol-trained nurse in the destination region and confirms availability.
- IMP, kits, consumables, and any equipment are shipped to the destination address under controlled conditions, with temperature monitoring where required.
- The nurse performs the visit, completes source documentation, and returns samples to the designated laboratory under the study’s logistics chain.
- Data flows to the site as it would for any other home visit, and the principal investigator retains oversight.
The participant experiences one appointment at their holiday accommodation. Everything else happens behind the scenes.
Which visit types can be delivered at a holiday address?
Not every assessment travels equally well. This is the practical breakdown that sponsors and study teams use when deciding what to protect during a travel window.
| Assessment type | Feasible at a holiday address? | Notes |
| Blood draws and biological sampling | Yes | Requires a local courier and laboratory routing plan |
| Vital signs, physical observations | Yes | Standard scope for a trained study nurse |
| IMP administration (oral, subcutaneous, intramuscular) | Yes | Depends on IMP stability, shipping conditions, and protocol |
| IMP dispensing and accountability | Yes | Requires controlled shipment and reconciliation documentation |
| Questionnaires, diaries, ePRO support | Yes | Often the easiest element to maintain remotely |
| Home-based EEG | Yes | Protocol-grade EEG can be recorded at a temporary address by a trained technician |
| Adverse event assessment and safety follow-up | Yes | Nurse reports to the investigator under the study’s safety reporting process |
| Imaging (MRI, CT, PET) | No | Requires a hospital or imaging facility; reschedule outside the travel window |
| Complex infusions requiring hospital monitoring | Usually no | Assess case by case with the medical monitor |
The rule of thumb: if the assessment does not require fixed hospital infrastructure, it can usually be delivered at a holiday address with sufficient lead time.
What has to be arranged before a nurse crosses a border
This is where cross-border home visits differ from domestic ones, and where most delays originate. Six elements need to be in place.
Qualified local personnel. Nursing qualifications and scope of practice are regulated nationally. The nurse performing the visit must be licensed to practice in the destination country and authorized to perform the specific acts the protocol requires, e.g. venipuncture, injection, IMP administration. Sending a nurse from the participant’s home country is generally not the solution. Using a qualified nurse from an established local network is.
Professional liability insurance valid in the destination. Coverage must be confirmed for the country where the visit takes place. This is a frequent source of last-minute cancellations when it is checked too late.
IMP logistics and temperature control. The IMP must reach the destination address in a validated shipping condition, with temperature excursion monitoring and a documented chain of custody. Customs handling applies for shipments crossing certain borders, and this drives the lead time more than anything else.
Sample return routing. Biological samples need a defined route from the holiday address to the central or local laboratory, within the stability window specified in the laboratory manual.
Regulatory and ethics position. Whether a home visit in another country is permissible depends on the study’s approvals, the destination country’s rules on trial activities, and the sponsor’s own position. This is a documented decision, not an assumption. It should be resolved before the participant travels, not while they are away.
Data protection. Personal data processed during the visit remains under the data privacy regulation and the study’s data protection framework. Contracts with local nursing providers must reflect this, including processor obligations and cross-border transfer arrangements where applicable.
How far in advance should a cross-border home visit be planned?
Plan a minimum of four to six weeks ahead for a cross-border home visit, and eight weeks where IMP shipment across customs borders is involved. Domestic home visits can often be arranged in one to two weeks.
The realistic constraint is rarely nurse availability. It is IMP shipping approval, insurance confirmation, and, where relevant, customs documentation. Study teams that build a travel-notification step into the informed consent discussion and the participant handbook get these requests weeks earlier, which is usually the difference between a completed visit and a protocol deviation.
Why this matters for sponsors and CROs
Protecting the visit schedule during travel is not a courtesy to participants. It affects three things sponsors measure.
Retention. Every avoided withdrawal is a recruitment slot that does not need to be refilled, and in rare disease studies, that slot may not be refillable at all.
Data completeness. Missed visits produce missing data points that complicate the statistical analysis and invite questions during inspection. A visit performed on time at a holiday address is a clean data point.
Participant experience and trial reputation. A study that accommodates normal life is a study people finish, and one they speak about positively. That reputation matters in tightly connected patient communities, particularly in rare disease.
There is also a geographic argument. The same capability that allows a nurse to visit a participant on holiday allows a sponsor to enrol participants who live far from any investigator site. The operational infrastructure is identical.
How Deltaclinical supports home visits abroad
Deltaclinical is a specialised CRO focused on decentralized clinical trials, home trial nursing, and home-based neurophysiology. We coordinate home visits worldwide, and cross-border visits for travelling participants are part of that scope.
What we provide:
- A network of qualified, study-trained nurses across multiple continents, so visits can be arranged in the destination region rather than dispatched from the participant’s home country
- Coordination of IMP shipment, temperature monitoring, and sample return routing to the destination address
- Verification of local licensing, scope of practice, and professional liability coverage before the visit is confirmed
- Protocol-specific training of the visiting nurse, with source documentation delivered to the site under the study’s standard process
- EEG@home. Protocol-grade home-based EEG for CNS and rare disease studies, recorded at the participant’s location by trained personnel
- A quality system built for sponsor and regulatory audit, including documented vendor qualification and GDPR-compliant data handling
Our role is to make the travel window a non-event: the site keeps oversight, the sponsor keeps the data point, and the participant keeps the holiday.
Frequently Asked Questions
Can a clinical trial participant travel abroad during a study?
In most studies, yes. Travel must be discussed with the investigator in advance, and any scheduled visits falling within the travel period need to be covered , either rescheduled inside the protocol window or performed as a home visit at the destination.
Who decides whether a home visit abroad is allowed?
The sponsor and the principal investigator, based on the protocol, the study’s regulatory approvals, and the rules of the destination country. The home visit provider confirms operational feasibility; the sponsor and investigator make the decision.
Can investigational medicinal product be shipped to a holiday address?
Often yes, depending on IMP stability, shipping conditions, and the destination. Shipments require validated temperature-controlled transport, monitoring, and documented chain of custody. Customs clearance for certain destinations adds lead time, which is why early notification matters.
Does a home visit abroad count as a protocol deviation?
No, provided the visit is performed within the protocol window, by qualified personnel, with correct source documentation, and under an arrangement approved by the sponsor and investigator. It is a completed visit, not a deviation.
What happens if a participant falls ill or has an adverse event while abroad?
Standard study safety procedures apply. The participant contacts the site using the emergency contact details provided at enrolment. The visiting nurse, where involved, reports observations to the investigator under the study’s safety reporting process.
Can home-based EEG be performed while a participant is travelling?
Yes. Home-based EEG does not require hospital infrastructure. With sufficient lead time, EEG@home recordings can be performed at a temporary address by trained personnel, using the same protocol-grade setup used at the participant’s home.
Planning a study with participants who travel, or facing a summer visit window you need to protect?
Contact Deltaclinical to discuss home visit coverage for your protocol.